Justice Delayed, Lives at Risk: The Stalled Legal Battle for Affordable Breast Cancer Treatment in India

In the corridors of the Kerala High Court, a quiet but profound struggle for the right to life is unfolding—a struggle that has been marked by staggering administrative inertia. At the heart of this legal odyssey is the accessibility of Ribociclib, a life-saving medication for patients suffering from advanced, hormone-receptor-positive (HR+) breast cancer. Despite the case being listed for final hearing 57 times, the wheels of justice have remained effectively frozen since early 2023, leaving thousands of women in a precarious state of uncertainty.

The Working Group on Access to Medicines and Treatment, a coalition of healthcare advocates and legal experts, has now taken the extraordinary step of writing to the Chief Justice of the Kerala High Court, Soumen Sen, as well as the President of India and the Chief Justice of India, urging immediate intervention to resolve this critical impasse.

The Magnitude of the Crisis: A Public Health Imperative

The urgency of the plea is underscored by the sobering reality of cancer morbidity in India. According to data from GLOBOCAN, the International Agency for Research on Cancer’s interactive database, India recorded over 1.9 lakh new breast cancer cases and nearly 98,337 deaths in 2022 alone. It remains the most prevalent cancer among Indian women and the leading cause of cancer-related mortality.

For those diagnosed with Luminal A (HR+/HER2-) breast cancer—an aggressive subtype capable of systemic spread—targeted therapies like Ribociclib and Abemaciclib are not merely medicinal options; they are essential survival tools. These medications can significantly halt disease progression, yet their availability is severely hampered by a "patent wall."

The Financial Burden: Prohibitive Costs vs. Patient Survival

The economic barrier to treatment is perhaps the most devastating aspect of this crisis. Ribociclib is currently priced at approximately ₹78,468 per month, while Abemaciclib ranges between ₹47,752 and ₹95,504 per month. While the 2026 Union Budget introduced a relief measure by exempting Ribociclib from basic customs duty, advocates argue that this reduction is merely a drop in the ocean. The annual cost of treatment remains north of ₹8.5 lakh, a figure that is insurmountable for the vast majority of Indian households, effectively rendering the medicine inaccessible to all but the most affluent.

Chronology of the Litigation

The legal battle for affordable access began in June 2022, when an original petitioner moved the Kerala High Court seeking a "Government Use License" under Section 100 of the Patents Act.

• June 2022: The initial writ petition is filed, requesting the government to invoke provisions that would allow for the local production of generic versions of the drug.
• The Demise of the Petitioner: Even after the passing of the original petitioner, the Kerala High Court took the commendable step of continuing the case suo motu, acknowledging that the matter transcends individual interest and touches upon a fundamental constitutional mandate.
• January 21, 2023: The last date on which the case saw substantive movement. Since then, the petition has been listed 57 times for a final hearing without ever reaching the presiding judge’s bench for argument.
• July 2026: After being listed on July 2, the case has been pushed forward to July 15, 2026, further extending the period of judicial inaction.

The Government’s Stance: A Disputed Definition of Urgency

The crux of the government’s opposition to the petition has been a narrow interpretation of public health emergencies. While the state has acknowledged the efficacy of Ribociclib, it has consistently refused to grant a Government Use License. The administration has argued that breast cancer, despite its staggering prevalence and mortality rate, does not constitute a "national urgency" warranting the bypass of patent protections.

Legal experts, including K.M. Gopakumar, co-convenor of the Working Group on Access to Medicines and Treatment, have strongly contested this. "The government has not yet provided a reasoned response regarding access to life-saving medicines and the enjoyment of the right to health," Gopakumar stated.

A Government Use License would allow for the manufacturing of generic versions of the drug—which are often 90% to 95% cheaper than the originator product—through domestic pharmaceutical channels. By refusing to exercise this power, critics argue, the state is prioritizing the interests of patent-holding corporations over the survival of its citizens.

Constitutional and International Implications

The delay in this case is not merely a procedural failure; it is a potential violation of the constitutional right to life. Article 21 of the Indian Constitution, as interpreted by the Supreme Court of India in numerous landmark judgments, includes the right to health as an inalienable component of the right to life. When the judiciary fails to address cases involving essential, life-saving medicines, it effectively denies patients the legal forum required to assert their fundamental rights.

Furthermore, India’s stance has international ramifications. Under the Doha Declaration on the TRIPS Agreement and Public Health, member nations are explicitly permitted to use "flexibilities" in patent law to protect public health. The Declaration emphasizes that the TRIPS Agreement should not prevent members from taking measures to protect public health and promote access to medicines for all.

By failing to utilize these flexibilities for a disease as pervasive as breast cancer, India risks undermining its own international commitments and its position as the "pharmacy of the world."

The Road Ahead: Why Judicial Timeliness Matters

The Working Group on Access to Medicines and Treatment, in their correspondence to the President and the Chief Justices, has highlighted that the cost of delay is measured in lives. As the court pushes the hearing dates further into the future, the window of opportunity for many patients to benefit from these targeted therapies is closing.

"Breast cancer disproportionately impacts women’s health, and access to life-saving medicines is essential for reducing preventable deaths," the group noted in their formal appeal. They argue that the judiciary must act with a sense of urgency commensurate with the disease’s progression.

As the July 15, 2026 hearing approaches, the eyes of the public health community are fixed on the Kerala High Court. Will the court finally address the constitutional obligations of the government? Or will the case continue to languish in the procedural limbo that has already cost too many lives?

The resolution of this case could set a vital precedent for how India manages the tension between intellectual property rights and the fundamental right to healthcare. For now, however, the patients waiting for affordable Ribociclib are left in a state of agonizing uncertainty, hoping that the court will recognize that for them, justice delayed is truly justice denied.